JO
HZNP

John Overdeck’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

John Overdeck’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-28,100
Closed -$3.08M – 5155
2021
Q3 		$3.08M Buy
28,100
+21,100
+301% +$2.19M 0.01% 1590
2021
Q2 		$655K Buy
+7,000
New +$644K ﹤0.01% 2867
2019
Q4 		– Sell
-11,800
Closed -$321K – 4185
2019
Q3 		$321K Buy
+11,800
New +$305K ﹤0.01% 2924
2016
Q2 		– Sell
-23,000
Closed -$381K – 3401
2016
Q1 		$381K Buy
+23,000
New +$402K ﹤0.01% 2239

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

John Overdeck's HZNP Position: Q4 2023 in Review

John Overdeck sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 16,100 shares — an estimated $1.86M sold.

John Overdeck first reported a position in HZNP in Q3 2013 and held it in 27 quarters. The position peaked at $34.7M in Q3 2020. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • John Overdeck reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • John Overdeck sold 16,100 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.86M.
  • John Overdeck first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 27 quarters.
  • John Overdeck's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $34.7M in Q3 2020.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Two Sigma Investments's 13F filing for Q4 2023, filed 14 Feb 2024.